Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the agency’s first in this type of implant that takes a potentially safer route ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

MISSISSAUGA, ON, June 23, 2025 /CNW/ - Edwards Lifesciences Corporation today announced the company's EVOQUE tricuspid valve replacement system has received Health Canada's approval for the treatment ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment ...

Last month, Edwards Lifesciences recalled its SAPIEN 3 Ultra Delivery System after reports of burst balloons during implantation, resulting in significant difficulty retrieving the valve into the ...

Edwards Lifesciences has received the US Food and Drug Administration (FDA) approval for its SAPIEN M3 mitral valve replacement system. It is said to be the first transcatheter therapy using a ...

Edwards Lifesciences stock reflects a business increasingly driven by transcatheter heart valve procedures, with recent quarterly figures showing revenue and profit growth that underpin the group’s ...

Edwards Lifesciences Corp EW shares are up on Friday as the company reported strong first-quarter results, highlighting growth in its transcatheter mitral and tricuspid therapies. • Edwards ...

NYON, Switzerland--(BUSINESS WIRE)--Edwards Lifesciences today announced the launch in Europe of the SAPIEN 3 transcatheter pulmonary valve implantation (TPVI) system with Alterra adaptive prestent, ...

Edwards Lifesciences remains in focus after its most recent quarterly report and updates on heart valve and critical care products. Investors are watching how procedure volumes, innovation spending ...